Final Results From Arq 197-209: A Global Randomized Placebo-Controlled Phase 2 Clinical Trial Of Erlotinib Plus Arq 197 Versus Erlotinib Plus Placebo In Previously Treated Eger-Inhibitor Naive Patients With Advanced Non-Small Cell Lung Cancer (Nsclc)